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Background: Deteriorated quality of life (QOL) is a
major problem in osteoporotic women. However,
little is known regarding the determinants of QOL
in patients with osteoporosis.
Objective: Our aim was to explore the role of
vitamin D status on QOL score in osteoporosis with
high fracture risk.
Methods: Patients were osteoporotic women aged
Z70 years and with Z1 risk factor for incident
fracture, namely prevalent osteoporotic fracture, bone
mineral density (BMD) 4–3.0 SD of young adult
mean, or high bone turnover marker. Health-related
QOL was assessed using the Japanese Osteoporosis
Quality of Life Questionnaire (JOQOL). When pa-
tients were classiﬁed into quartiles by total QOL
score). Serum 25-hydroxyvitamin D (25[OH]D) level
was measured by immunoassay.
Results: A total of 1585 osteoporotic women were
included in the study (age range, 70–95 years). Age,
body mass index, serum 25(OH)D status (low, nor-
mal, or high), bone mineral density, number of*Members of the A-TOP Research Group are listed in the
Acknowledgments.
February 2014prevalent vertebral fractures, presence of hyperten-
sion, presence of osteoarthritis, and history of falls
were signiﬁcantly correlated with QOL quartile. Mul-
tivariate liner regression analysis indicated that low
serum 25(OH)D level (o20 ng/mL) was an independ-
ent determinant of total QOL score quartile (P ¼
0.0055). The conventional determinants of QOL—age
(Po 0.0001), body mass index (P ¼ 0.0060), number
of prevalent vertebral fractures (P o 0.0001), pres-
ence of osteoarthritis (P ¼ 0.0074), and history of fall
(P ¼ 0.0098)—were also independent determinants of
total QOL score.
Conclusions: These results strongly suggest that
low serum 25(OH)D level was a signiﬁcant determi-
nant of QOL in these osteoporotic women, independ-
ently of the conventional factors that reduce QOL.
Maintenance of serum 25(OH)D levels 420 ng/mLAccepted for publication December 7, 2013.
http://dx.doi.org/10.1016/j.clinthera.2013.12.007
0149-2918 & 2014 The Authors. Published by Elsevier, Inc.
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Clinical Therapeuticsmay be required to maintain patients’ QOL in osteo-
porosis. (Clin Ther. 2014;36:225–235) & 2014 The
Authors. Published by Elsevier, Inc.
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INTRODUCTION
Osteoporosis is characterized by deteriorated bone
strength.1 It is a national burden in an aging society
such as that in Japan, because of the high
susceptibility to bone fractures in patients with
osteoporosis, which can result in impaired quality of
life (QOL),2–4 and is also associated with increased
morbidity and mortality in both white and Asian
populations.5–11 Therefore, the prevention of osteo-
porotic fractures is a primary end point of treatment
because of socioeconomic aspects and patient survival.
Although several kinds of drugs are available to
prevent fractures,12 sufﬁcient prevention of
osteoporotic fractures has not been achieved, and an
inadequate clinical outcome of osteoporosis treatment
has been associated with decreased QOL scores.13 In
this context, maintenance or improvement of patients’
QOL is required in clinical practice. Recent progress
in the treatment of osteoporosis has indicated that
teriparatide administration improves patients’
QOL.14,15 However, the duration of teriparatide use
is limited to only 2 years. Bisphosphonates or calcito-
nin are other options for the improvement of deterio-
rated QOL.16 To achieve further improvement of
deteriorated QOL, exploration of modiﬁable risks
for the deterioration of QOL would be required.
Until now, several factors related to the deteriora-
tion of QOL or disability have been reported, such as
age, number of prevalent vertebral fractures, low bone
mineral density (BMD), pain, and coexisting osteo-
arthritis.17–24 However, there is little known evidence
regarding the speciﬁc modiﬁable factors that are
associated with patients’ QOL.
Vitamin D insufﬁciency and deﬁciency, which are
common in the elderly population, are directly con-
nected with various morbidities in elderly people.25,26
Bone fractures, falls, immune dysfunction, and even
increasing mortality have been reported to be associ-
ated with vitamin D insufﬁciency.10 Moreover, the
effects of vitamin D supplementation on the
prevention of fractures,27 falls,28,29 and cancers30,31
Open access under CC BY-NC-ND license.226and on physical function32,33 have been extensively
investigated. These reports raise an expectation that
serum 25(OH)D level may have an effect on individ-
ual QOL. However, little had been known regarding
the relationship between serum 25(OH)D levels and
QOL in osteoporosis. Our aim was to explore the role
of vitamin D status on QOL score in osteoporosis
with high fracture risk.
PATIENTS AND METHODS
Ethical Considerations
The present study was conducted in accordance
with the Declaration of Helsinki. All of the patients
provided written informed consent. The protocol was
reviewed and approved by a central ethical committee
(chair, Dr. Rikushi Morita) and was also reviewed by
the institutional review board at each institution as
necessary.
Inclusion and Exclusion Criteria
Eligible patients were outpatients with postmeno-
pausal osteoporosis enrolled in the Japanese Osteopo-
rosis Intervention Trial (JOINT)-02, which was
conducted to verify the effect of combination therapy
with alendronate and alfacalcidol compared to mono-
therapy with alendronate alone nationwide in Japan.34
Patients were diagnosed based on the diagnostic criteria
established by the Japanese Society for Bone and
Mineral Research,35 aged Z70 years, and had Z1
risk factor for incident fracture (1–4 prevalent
vertebral fractures between T4 and L4, BMD r
percentage of the young adult mean [%YAM] –3.0
SD, or high bone turnover marker). The participants in
the present study were residents of the local community
without high dependency, and institutionalized patients
were excluded. We also excluded patients who had
metabolic bone diseases other than osteoporosis, severe
degenerative deformation of the spine from T4 to L4,
hypothyroidism, hyperparathyroidism, or critical illness.
Patients who had received some bisphosphonates in the
6 months before enrollment were also excluded from
this study because of possible modiﬁcation of patients’
QOL at registration. Patients with dementia were
excluded because the patients were required to respond
to the QOL questionnaire and to provide written
informed consent. All patients were questioned
carefully at baseline regarding their previous treatment
for osteoporosis (yes or no) and complications such as
hypertension, diabetes mellitus, dyslipidemia, rheumatoidVolume 36 Number 2
H. Ohta et al.arthritis, or osteoarthritis. Participants were also
questioned regarding history of falls.
Health-Related QOL Measurement
We used the Japanese Osteoporosis Quality of Life
Questionnaire (JOQOL), which was established by the
Japanese Society for Bone and Mineral Research, to
measure and assess QOL in Japanese osteoporotic
patients. The JOQOL instrument consists of 6 domains
and 38 items, based on the Osteoporosis Assessment
Questionnaire36 and the Quality of Life Questionnaire
of the European Foundation of Osteoporosis,37 with
some added questions involving Japanese lifestyle.
Higher scores indicated better QOL. A validation
study of the JOQOL was previously conducted and
the reliability and validity of its questionnaire in
Japanese osteoporotic patients were veriﬁed.38 A
patient0s response to each item was scored with a
points scale from 0 to 4, and the maximum total
score of all the responses was 152 points. The number
of items and subscale scores per domain were as
follows: pain (5 items; 20 points), activities of daily
living (16; 64), recreational and social activity (5; 20),
general health (3; 12), posture and ﬁgure (4; 16), and
fall and psychological effect (5; 20). Each patient was
asked to complete a self-report questionnaire at base-
line. The total score and subscale scores per domain
were calculated and converted into corresponding values
on a 100-point scale (0 ¼ poor to 100 ¼ perfect QOL)
Japan Clinical Research Support Unit (Tokyo, Japan).
Diagnosis of Prevalent Vertebral Fractures
We collected anteroposterior and lateral radio-
graphs of the thoracic and lumbar spine at baseline.
Prevalent vertebral fractures were diagnosed by a
central committee without any information on the
patients. The diagnoses of the prevalent vertebral
fractures were judged semiquantitatively using the
diagnostic criteria for prevalent vertebral fractures.39
Measurements of Biochemical Parameters
For serum levels of 25(OH)D, intra- and interassay
variance were 5.96% to 6.99% and 7.09% to
10.82%, respectively, and the minimal measurement
was 3.4 ng/mL. 25(OH)D was measured by immuno-
assay (DiaSorin Inc, Stillwater, Minnesota) in a central
laboratory (SRL, Tokyo, Japan). Serum creatinine
level was measured by autoanalyzer at each institu-
tion, and estimated glomerular ﬁltration rate (eGFR)February 2014was calculated using a formula proposed by the
Japanese Society of Nephrology,40 as follows:
eGFR (mL/min/1.73 m2) ¼ (194  Cr–1.094
 Age–0.287)  0.739
The eGFR was classiﬁed into 3 categories, as
follows:Z90 mL/min/1.73 m2, chronic kidney disease
grade 1; 60–o90 mL/min/1.73 m2, grade 2; and o60
mL/min/1.73 m2, grade 3.
Measurement of BMD
BMD was measured in each institution by dual-
energy x-ray absorptiometry for the lumbar spine,
femoral neck, or distal site of the radius, or by micro-
densitometry for the left second metacarpal bone. The
values were expressed in terms of %YAM.35
Statistical Analysis
The data for numerical variables are expressed as
mean (SD) values. We assessed whether several base-
line factors were associated with QOL total and
subscale scores. ANOVA was performed to assess
differences in continuous variables (age, BMI, eGFR,
years since menopause, serum 25[OH]D level, and
BMD). Mantel-Haenszel χ2 test was used to assess
differences among categorical variables (number of
prevalent vertebral fractures, comorbidity, history of
fall, and prior treatment). The determinants of total
QOL score were analyzed using an adjusted linear
regression model. Moreover, a multiple linear regres-
sion model was applied to investigate the relationship
between QOL scores (total score and subscale scores)
and serum 25(OH)D concentration. A category of
serum 25(OH)D of Z30 ng/mL was used as the
reference group. This analysis was performed on a 2-
step basis, as follows: ﬁrst, unadjusted (model 1);
second, adjusted for all confounders that had
the association of P value o0.1 with total QOL
score (model 2) using a multiple linear regression
model. All analyses were performed using SAS release
9.1 software (SAS Institute Inc, Cary, North Carolina).
RESULTS
Background Characteristics of the Patients
A total of 1710 patients who responded to the
QOL questionnaire from 186 institutions nationwide
participated in the present study. The participants in
whom the serum 25(OH)D levels were not measured
were excluded (n ¼ 125). Finally, a total of 1585227
Clinical Therapeuticspatients were recruited to the present study. The mean
age was 76.5 years (range, 70–95 years), and the
mean (SD) BMI was 23.2 (3.6) and eGFR was 68.2
(18.4) mL/min/1.73 m2. Mean BMD (%YAM) of all
measured sites was o70% of Japanese diagnostic
threshold of osteoporosis. The mean (SD) total QOL
score was 65.8 (15.3). About 60% of the patients had
Z1 prevalent vertebral fracture. A total of 1138 of
1585 participants (71.8%) had Z1 comorbidity other
than osteoporosis. The mean serum 25(OH)D level
was 23.7 ng/mL. Serum 25(OH)D levels were divided
into three categories, namely o20 ng/mL (n ¼ 376,
23.7% as low group), 20 to 30 ng/mL (n ¼ 982,
62.0% as moderately low group) and Z30 ng/mL
(n ¼ 227, 14.3% as normal/reference group).
Association Between Quartiles of QOL Score and
Baseline Variables
The total QOL score was classiﬁed into quartiles as
shown in Table I.
ANOVA between the quartiles of total QOL score
and the numerical variables indicated that the baseline
age (Po 0.0001), BMI (P ¼ 0.0043), 25(OH)D (PoTable I. Association between quartiles* of JOQOL total
Parameter
1st Quartile 2nd Quar
n Mean (SD) n Mean
QOL score
Mean  SD 387 44.8 (10.4) 404 63.5
Range 7.9–57.2 57.9
Age, years 387 78.1 (4.8) 404 76.9
BMI, kg/m2 385 23.5 (4.1) 403 23.3
eGFR, mL/min/1.73m2 373 68.4 (20.9) 377 68.2
YSM 354 49.1 (4.8) 387 49.1
25(OH)D, ng/mL
Total sample 387 22.7 (6.2) 404 23.4
Winter þ 175 22.3 (6.5) 176 23.4
Summerþþ 212 23.1 (6.0) 228 23.4
BMD, %YAM
Lumbar 116 64.2 (12.7) 115 64.1
Radial 113 58.6 (11.3) 151 60.9
Metacarpal, Al mm equivalent 115 65.5 (10.4) 100 68.7
Femoral neck 21 63.8 (9.4) 15 56.5
All sites 365 62.9 (11.7) 381 63.7
AI ¼ aluminum; JOQOL ¼ Japanese Osteoporosis Quality of Li
April to September; Winter þ ¼ 25(OH)D measured during Oc
*QOL quartiles were deﬁned by the following QOL total score
(fair); quartile 3, 69.1–77.0 (good); quartile 4: 77.6–94.7 (very
2280.0001), and BMD at the radius (P ¼ 0.0027) and
metacarpal bone (P ¼ 0.0034) were associated with
quartiles of total QOL score (Table I). The trend
analysis using Mantel-Haenszel χ2 test between the
quartiles of total QOL score and categorical variables
is indicated in Table II. The baseline number of
prevalent vertebral fractures (P o 0.0001), existing
comorbidities (P ¼ 0.016), especially hypertension
(P ¼ 0.010) and osteoarthritis (P o 0.0001), and
history of fall (P ¼ 0.0003) were associated with the
quartiles of total QOL score. A history of having
received any treatment for osteoporosis before
enrollment was not associated with the quartile of
QOL (P ¼ 0.10) (Table II).
QOL Scores and 25(OH)D Level
The association between serum 25(OH)D levels
and total QOL scores is shown in Figure 1. Lower
serum 25(OH)D levels were associated with lower
QOL score, and this trend appeared prominently in
patients with levels o20 ng/mL (P o 0.0001) (Figure
1A). In consideration of confounding, the data were
adjusted for age, BMI, BMD, number of prevalentscore and baseline numerical variables (N ¼ 1585).
tile 3rd Quartile 4th Quartile
P(SD) n Mean (SD) n Mean (SD)
(3.2) 406 73.2 (2.4) 388 82.7 (3.9) —
–68.4 69.1–77.0 77.6–94.7
(4.7) 406 76.0 (4.7) 388 75.0 (4.3) o0.0001
(3.6) 403 23.3 (3.4) 387 22.7 (3.2) 0.0043
(17.5) 378 66.9 (17.3) 358 69.1 (17.4) 0.89
(4.1) 378 48.6 (4.7) 370 49.0 (4.3) 0.35
(5.5) 406 24.1 (5.4) 388 24.6 (5.5) o0.0001
(5.3) 175 24.4 (4.8) 176 24.0 (5.3) 0.0003
(5.6) 231 23.9 (5.8) 212 25.0 (5.6) 0.0018
(11.4) 101 64.3 (11.7) 105 65.6 (10.9) 0.40
(11.2) 185 62.8 (10.4) 179 62.2 (9.7) 0.0027
(10.0) 97 67.3 (9.1) 83 70.5 (11.1) 0.0034
(10.2) 4 65.1 (10.2) 12 64.1 (3.8) 0.74
(11.4) 387 64.4 (10.6) 379 65.0 (10.7) 0.0061
fe Questionnaire; Summerþþ¼ 25(OH)D measured during
tober to March; YSM ¼ years since menopause.
ranges: quartile 1, 7.9–57.2 (poor); quartile 2, 57.9–68.4
good).
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Table II. Association between quartiles* of JOQOL total score and baseline categorical variables (N ¼ 1585).
Values are number (%) of patients.
Categorical Variable
1st Quartile
(n ¼ 387)
2nd Quartile
(n ¼ 404)
3rd Quartile
(n ¼ 406)
4th Quartile
(n ¼ 388) P
No. of prevalent vertebral fractures o0.0001
0 118 (30.5) 145 (35.9) 184 (45.3) 201 (51.8)
1 114 (29.5) 133 (32.9) 125 (30.8) 111 (28.6)
Z2 154 (39.8) 126 (31.2) 97 (23.9) 74 (19.1)
Comorbidities 295 (76.2) 286 (70.8) 296 (72.9) 261 (67.3) 0.016
Hypertension 189 (48.8) 187 (46.3) 184 (45.3) 153 (39.4) 0.010
Diabetes mellitus 46 (11.9) 31 (7.7) 36 (8.9) 37 (9.5) 0.38
Dyslipidemia 73 (18.9) 78 (19.3) 85 (20.9) 87 (22.4) 0.18
Rheumatoid arthritis 1 (0.3) 5 (1.2) 2 (0.5) 5 (1.3) 0.26
Osteoarthritis 166 (42.9) 148 (36.6) 159 (39.2) 107 (27.6) o0.0001
History of fall 61 (15.8) 40 (9.9) 28 (6.9) 34 (8.8) 0.0003
History of pretreatment 130 (33.6) 137 (33.9) 125 (30.8) 112 (28.9) 0.10
JOQOL ¼ Japanese Osteoporosis Quality of Life Questionnaire.
*Quartiles were deﬁned by the following QOL total score ranges: quartile 1, 7.9–57.2 (poor); quartile 2, 57.9–68.4 (fair);
quartile 3, 69.1–77.0 (good); quartile 4: 77.6–94.7 (very good).
H. Ohta et al.vertebral fractures, hypertension status, osteoarthritis
status, and history of fall (Figure 1B). After
adjustment, although the total QOL scores for
patients with levels o20 ng/mL were slightly higher,
the scores consistently deteriorated in those patients
compared with the group with higher serum 25(OH)D
levels (P ¼ 0.0013) (Figure 1B).Determinants of Total QOL Score
The determinants of total QOL score, as analyzed
using an adjusted linear regression model, are indi-
cated in Table III. Age (P o 0.0001), BMI (P ¼
0.0060), low 25(OH)D (o20 ng/mL) (P ¼ 0.0055),
number of prevalent vertebral fractures (Po 0.0001),
presence of osteoarthritis (P ¼ 0.0074), and history
of fall (P ¼ 0.0098) were signiﬁcant independent
determinants of total QOL score, whereas the
relationship between hypertension and total QOL
score was not signiﬁcant after adjustment for the
confounding factors.
The relationship between serum 25(OH)D levels and
each domain of QOL are shown in Table IV. The scores
on the domains of activities of daily living and
recreational and social activity domains in the patientsFebruary 2014with serum 25(OH)D levels o20 ng/mL were
signiﬁcantly lower compared with those in the group
with serum 25(OH)D levels Z30 ng/mL (reference
group) in model 1 (unadjusted) (estimates [95% CI],
–5.92 [–9.09 to –2.75] and –6.42 [–9.98, - to –2.87],
respectively; P ¼ 0.0003 and 0.0004). After adjust-
ment for age, BMI, BMD, number of prevalent
vertebral fractures, hypertension status, osteoarthritis
status, and history of fall (model 2), the subscale scores
of activities of daily living and recreational and social
activity domains in the group o20 ng/mL were
signiﬁcantly lower compared with those in the
reference group (estimates [95% CI], –3.62 [–6.61 to
–0.63] and –5.59 [–9.17 to –2.01]; P ¼ 0.018 and
0.0022). These ﬁndings were not observed in the other
4 domains (pain, general health, posture and ﬁgure, and
fall and psychological effect). Furthermore, the subscale
scores of all domains were not signiﬁcantly lower in the
group with serum 25(OH)D level 20 to o30 ng/mL
compared with those in the reference group.DISCUSSION
We investigated the determinants of QOL in osteo-
porotic women with high fracture risk. Age, number229
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Figure 1. Relationship between total quality-of-life (QOL) scores and serum 25-hydroxyvitamin D (25[OH]D)
concentrations (N ¼ 1585). (A) Unadjusted (P o 0.0001); (B) Adjusted for age, number of
prevalent vertebral fractures, and falls (P ¼ 0.0013). The lower serum 25(OH)D levels were
associated with the lower total QOL scores.
Clinical Therapeuticsof prevalent vertebral fractures, BMI, history of fall,
osteoarthritis status, and BMD were independently
associated with QOL quartile in these osteoporotic
patients. Number of prevalent vertebral fractures is a
well-known factor of disability in osteoporotic pa-
tients.17,18 Osteoarthritis in the vertebrae or knee
joints is a risk for deteriorated QOL in the general
population.19,20 Obese patients have been reported to
have impaired QOL scores,41 and the association of
osteoarthritis with obesity has been well-documented.
In addition to the presence of osteoarthritis, we
recently reported that obesity is a risk factor for230vertebral fracture in postmenopausal women.42 The
results of the present study did not conﬂict with those
previous data, although the present results were
limited only to osteoporosis with high fracture risk.
In addition to the conventional factors known to
deteriorate QOL, the present study demonstrated that
low serum 25(OH)D (o20 ng/mL) was associated with
QOL quartile. Wicherts et al43 reported that serum 25
(OH)D levels were associated with physical performance
in elderly people. Patients with lower vitamin D level
showed poorer QOL scores in Turkish osteoporotic
women.44 The present study, together with the previousVolume 36 Number 2
Table III. Determinants of total QOL score (N ¼ 1585).*
Determinant Point Estimate 95% CI P
Age (5-y increments) –3.08 –3.86 to –2.30 o0.0001
BMI (5-kg/m2 increments) –1.50 –2.56 to –0.43 0.0060
25(OH)D, ng/mL
o20 (low) –3.41 –5.81 to –1.00 0.0055
20–o30 (moderately low) 0.083 –2.02 to 2.19 0.94
Z30 (normal/reference) Reference — —
BMD (YAM%) (5% increments) 0.29 –0.054 to 0.62 0.10
No. of prevalent vertebral fractures –2.98 –3.87 to –2.09 o0.0001
Hypertension –0.76 –2.24 to 0.72 0.31
Osteoarthritis –2.06 –3.56 to –0.55 0.0074
History of fall –3.13 –5.51 to –0.76 0.0098
25(OH)D ¼ 25-hydroxyvitamin D; BMD ¼ bone mineral density; BMI ¼ body mass index; QOL ¼ quality of life; YAM% ¼
percentage of the young adult mean.
*The determinants for total QOL score were analyzed by adjusted linear regression model, using the 8 baseline factors
signiﬁcantly associated with total QOL score.
H. Ohta et al.studies, may indicate that a direct connection between
the QOL and serum 25(OH)D level may exist, and
therefore that the maintenance of adequate serum 25
(OH)D level is important in terms of fracture prevention
or maintaining better QOL. The difference in total QOL
scores in the lowest and highest groups of serum 25
(OH)D was 10 points, which has been considered to
have clinical and social relevance.45
Recent reports led us to review the biological
actions of vitamin D. It has been reported that vitamin
D is connected to a wide range of biological actions to
regulate many activities, such as cell proliferation and
activity of the immune, cardiovascular, and muscular
systems.25,26 Several observational studies have
pointed to an association between serum 25(OH)D
level and falls and/or frailty, mainly focused on elderly
people. Among them, a prospective cohort study from
Amsterdam, the Netherlands, indicated that serum
levels o10 ng/mL were associated with a greater risk
for falls.46 Other observational studies have suggested
that serum 25(OH)D levelso20 ng/mL are associated
with greater frailty indices and likely an increased risk
for falls among elderly people, with considerable
heterogeneity.47 The inconsistencies of the effects of
vitamin D on frailty or falls may be related to the
differences in calcium intake, assay method of 25(OH)D,February 2014or the measurements of outcomes. Although the
patients in the present study were limited to
osteoporotic patients with a high risk for fracture, a
signiﬁcant correlation between QOL quartile and
serum 25(OH)D level was observed after adjustment
for confounding factors. Japan is a known country,
where the calcium intake is lower than the Western
countries. Since low calcium intake can be facilitate
the symptoms of vitamin D deﬁciency, it may be
possible that the effect of low vitamin D exposure on
QOL was more obvious in Japan than in Western
people.47
Our baseline analysis had several limitations. First,
the nutrition status of patients, sun exposure, frailty,
and similar factors were not measured, despite their
inﬂuence on serum 25(OH)D levels. Our results may
thus have included several additional confounding
factors. Second, the results of this study may not
apply to the entire osteoporotic population because
the inclusion criteria in this study were limited to
osteoporotic patients with a high risk for fracture and
aged Z70 years. Moreover, male osteoporotic pa-
tients were excluded from the present study. There-
fore, expansion of the study to a larger osteoporotic
population that includes both sexes may be required
in the future. However, most of the participants in the231
Table IV. Association between QOL subdomain scores and serum 25(OH)D using multiple linear regression
model (N ¼ 1585).
Domain and Score (mean [SD])/
25(OH)D Class, ng/mL
Unadjusted Adjusted*
Point Estimate 95% CI P Point Estimate 95% CI P
Pain (70.4 [22.2])
o20 (low) –1.74 –5.44 to 1.96 0.36 –1.48 –5.24 to 2.29 0.44
20–o30 (moderately low) 1.10 –2.13 to 4.33 0.50 1.28 –2.01 to 4.56 0.45
Z30 (normal/reference) Ref Ref
Activities of daily living (79.9 [19.7])
o20 (low) –5.92 –9.09 to –2.75 0.0003 –3.62 –6.61 to –0.63 0.018
20–o30 (moderately low) –0.74 –3.51 to 2.05 0.61 0.30 –2.31 to 2.91 0.82
Z30 (normal/reference) Ref Ref
Recreational and social activity
(44.3 [21.6])
o20 (low) –6.42 –9.98 to –2.87 0.0004 –5.59 –9.17 to –2.01 0.0022
20–o30 (moderately low) –0.74 –3.84 to 2.37 0.64 –0.48 –3.61 to 2.64 0.76
Z30 (normal/reference) Ref Ref
General health (42.8 [17.8])
o20 (low) –1.03 –3.98 to 1.92 0.49 –0.67 –3.69 to 2.34 0.66
20–o30 (moderately low) 1.02 –1.55 to 3.60 0.44 1.40 –1.23 to 4.03 0.30
Z30 (normal/reference) Ref Ref
Posture and ﬁgure (61.3 [22.3])
o20 (low) –2.80 –6.49 to 0.89 0.14 –2.07 –5.74 to 1.60 0.27
20–o30 (moderately low) –0.85 –4.08 to 2.37 0.60 –2.07 –3.47 to 2.93 0.87
Z30 (normal/reference) Ref Ref
Fall and psychological effect (59.2 [20.8])
o20 (low) –2.86 –6.29 to 0.57 0.10 –2.48 –6.00 to 1.04 0.17
20–o30 (moderately low) –0.13 –3.13 to 2.87 0.93 0.14 –2.93 to 3.21 0.93
Z30 (normal/reference) Ref Ref
Total score (65.8 [15.3])
o20 (low) –4.62 –7.09 to –2.16 0.0002 –3.41 –5.81 to –1.00 0.0055
20–o30 (moderately low) –0.47 –2.63 to 1.69 0.67 0.083 –2.02 to 2.19 0.94
Z30 (normal/reference) Ref Ref
25(OH)D ¼ 25-hydroxyvitamin D; QOL ¼ quality of life; Ref ¼ reference.
*Adjusted for age, body mass index, bone mineral density, number of prevalent vertebral fractures, hypertension,
osteoarthritis, and history of fall.
Clinical Therapeuticspresent study were managed by a primary care clinic,
and almost 70% of the patients had Z1 comorbidity,
some of which (eg, diabetes mellitus, rheumatoid
arthritis, osteoarthritis) may be excluded from drug-
development trials. Therefore, the evidence obtained
from the present study may be more easily applicable
to patients with osteoporosis with a high fracture risk
visiting a general practice clinic than the evidence
obtained from drug-development trials. Third, it has232been well-established that serum levels of 25(OH)D
show signiﬁcant seasonal variation, which may have
been a considerable confounder when the relationship
between QOL score and serum 25(OH)D level was
evaluated. In addition, latitude of the residency may
also be affected by serum 25(OH)D level. However,
the present study design did not include considerations
of these confounders. Therefore, adjustments for these
confounders on the present core results may beVolume 36 Number 2
H. Ohta et al.insufﬁcient. Finally, because the present study was
performed with a cross-sectional design, whether a
low serum 25(OH)D level is a causative factor of
deteriorated QOL remains uncertain.
Although several limitations were present in this
study, our results may lead us to promote improve-
ment of vitamin D nutrition in osteoporotic patients
with a high fracture risk. Several studies have assessed
the effects of vitamin D on QOL in the elderly
population, using standard instruments of QOL.48–50
However, these studies were not focused on QOL in
osteoporosis. The discordant results may have been
the result of different populations and different out-
comes. Further prospective interventional study in
osteoporosis as to whether vitamin D supplementation
with or without sufﬁcient calcium intake promotes
patients’ QOL will be required.
CONCLUSIONS
The present ﬁndings regarding the association of QOL
score with serum 25(OH)D level may support the
recommendation to measure and maintain an ad-
equate level of serum 25(OH)D in osteoporotic
patients to prevent the deterioration of QOL in
addition to preventing fractures.
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